Clinical Trials Browser

Breast Neoplasms, Neoplasm, Residual

NCT06134375 2026-03-12

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Phase 1/2 Recruiting

204 enrolled

Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03384914 2026-03-06

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

Phase 2 Active not recruiting

119 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Breast Neoplasms, Male

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

976 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual

NCT07069595 2026-03-05

PREDICT-RD

Phase 2 Recruiting

78 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07211178 2026-03-04

GEMINI Breast

Recruiting

900 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07025785 2026-01-15

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Phase NA Recruiting

100 enrolled

Breast

Breast Neoplasms, Lymphatic Metastasis, Neoplasm, Residual

NCT06663787 2025-11-28

HER2 CR

Active not recruiting

50 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT03945721 2025-09-29

UNITY

Phase 1 Active not recruiting

21 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT05196087 2025-07-02

NIP IT!

Recruiting

500 enrolled

BreastDermatologicEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Breast Neoplasms, Melanoma, Neoplasm, Residual

NCT04674306 2025-05-23

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer

Phase EARLY_PHASE1 Active not recruiting

35 enrolled

Breast

Neoplasm, Residual, Triple Negative Breast Neoplasms

Clinical Trials

FLAMINGO-01

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

MiRaDoR

PREDICT-RD

GEMINI Breast

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

HER2 CR

UNITY

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

NIP IT!

Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer